Latest news with #Huma
United News of India
5 days ago
- Entertainment
- United News of India
Awestruck by beauty of Patnitop: Bollywood actress Huma Qureshi in Jammu region
Jammu, May 29 (UNI) Bollywood actress Huma Qureshi on Thursday said that she was awestruck by the beauty of Patnitop tourist destination in Jammu region. Huma, on the second day of her visit to the Jammu region, explored the scenic landscapes of Patnitop and Nathatop, where she experienced a firsthand taste of adventure through activities such as camping and nature walks. At Skyview by Empyrean, Patnitop, she took a ride on the highest gondola in Asia above the tree line, a marvel of engineering constructed without cutting a single tree. The initiative stands as a significant step towards eco-tourism and sustainable tourism practices in Jammu and Kashmir. Officials urged her to encourage more celebrities to visit and promote the scenic and cultural richness of Jammu. Speaking on the occasion, Huma Qureshi said that she was absolutely awestruck by the beauty of Patnitop. She added that the warmth and hospitality of the people here are truly unmatched. Referring to the larger Jammu region, she mentioned that destinations like Katra, Bhaderwah, Bani, Billawar, Basohli, Marwah-Warwan, Rajouri, Poonch and several others are blessed with abundant natural beauty and rich cultural heritage. She further stated that Jammu and Kashmir is safe, serene, and one of the most breathtaking destinations in India. She wholeheartedly invited all tourists from across the country and the world to come, explore and experience this unmatchable beauty of Jammu and Kashmir. During her visit to Skyview by Empyrean, Huma Qureshi interacted with officials and stakeholders including Deputy Commissioner Udhampur, Saloni Rai, Director Tourism Jammu, Vikas Gupta, CEO Patnitop Development Authority, Devander Singh Bhau, Joint Director Tourism Jammu, Aijaz Qaiser and members of the Patnitop Hotels Association, where discussions were held on strengthening tourism prospects in the region. Later in the day, she visited some of the well-known restaurants in Jammu city, where she enjoyed the authentic local flavors including GI-tagged Kalari Kulcha, Anardana Chutney, Gucchi Pulao, Rajma and other traditional delicacies. Director Tourism Jammu informed that the visit was planned as part of a strategic initiative to promote the diverse tourist destinations of the Jammu region. He added that more celebrity visits are scheduled in the coming days, with the aim of showcasing the region's potential and inviting tourists from across India and around the world to experience the unmatched beauty and cultural vibrancy of the region. The members of the Patnitop Hotels and Restaurant association wholeheartedly thanked the Government of J&K, Commissioner/Secretary Tourism, Yasha Mudgal and Director Tourism Jammu for conceptualising and supporting this initiative. They also extended their full support for similar promotional events in the future to strengthen Jammu's position on the national and international tourism map. Huma Qureshi's visit marks the beginning of a focused campaign by the Directorate of Tourism, Jammu, aimed at rebuilding traveller confidence and showcasing Jammu as a prime destination for adventure, culture, cuisine and natural beauty. This initiative is expected to significantly boost the tourism profile of the region. UNI VBH RN
Forbes
20-05-2025
- Business
- Forbes
Nvidia's AI Ecosystem Masterplan Is Driving Its Stock
Nvidia (NASDAQ:NVDA) shares have increased by nearly 11% in the last week, and is still up almost 40% over the last 30 days. While wider markets have risen after China and the U.S. declared a 90-day halt on tariffs, which is considered a step toward de-escalating the global trade conflict, there have also been a number of company-specific positives for Nvidia as well. Nvidia has introduced NVLink Fusion, a new interconnect technology for chip-to-chip communications that aims to enhance the capabilities of AI systems. Importantly, the company indicates that it will license this technology to other chip designers, allowing them to develop rapid and high-performing custom AI chips. This enables third-party providers to construct semi-custom AI systems that still integrate with Nvidia's ecosystem. This strategy broadens Nvidia's reach within the custom AI hardware sector beyond its own products. Firms like Marvell and MediaTek intend to integrate Fusion into their custom AI system designs. This could be a strategic long-term initiative for Nvidia, as it may encourage companies to commit to its software suite. It could be a move towards Nvidia establishing de facto standards for AI hardware, similar to how Intel influenced the PC sector with its x86 architecture. During President Donald Trump's trip to the Middle East earlier this month, Nvidia CEO Jensen Huang declared that the company would deliver over 18,000 Blackwell AI chips to an AI startup based in Saudi Arabia called Humain, for application in its AI data centers. The so-called 'sovereign AI' sector, which encompasses government-sponsored projects to establish domestic AI capabilities, is gaining significant importance for Nvidia as it seeks to lessen its dependency on American technological giants. Various companies, including Amazon, Meta, Google, and Microsoft, are collectively estimated to make up more than 50% of Nvidia's revenue. Many of these corporations are also working on their own AI chips, making it even more critical for Nvidia to balance its investments. Currently, the rise in NVDA stock over the past four years has been anything but steady, with annual returns being much more erratic than the S&P 500. The stock achieved returns of 125% in 2021, -50% in 2022, 239% in 2023, and 171% in 2024. The Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, displays significantly lower volatility. Furthermore, it has consistently surpassed the S&P 500 in the last four years. What accounts for that? Overall, HQ Portfolio stocks have demonstrated superior returns with reduced risk compared to the benchmark index, providing a smoother ride as reflected in HQ Portfolio performance metrics. Considering the current unpredictable macroeconomic context concerning interest rate reductions and various conflicts, could NVDA find itself facing a similar predicament as in 2022 and underperform the S&P in the coming year, or will it experience a robust upturn? We estimate Nvidia's stock at approximately $101 per share, about 25% lower than the present market value. Explore our evaluation of Nvidia valuation: Is it Overpriced or Underpriced?. Several factors contribute to our current pessimism regarding the stock. We foresee a potential decline in the enthusiasm surrounding AI applications that has driven gains over the past two years, as marginal performance improvements from larger models diminish, alongside challenges in accessing high-quality training data. This transition towards more efficient models could aggravate the effects of a prospective slowdown for GPU manufacturers, including Nvidia. Even though Nvidia stock has been an outstanding performer over recent years, shares can decline rapidly – by 20%, 30%, or even 50% – as has been observed during previous market crashes. No stock is invulnerable. What is the lowest Nvidia stock could fall to in a market collapse? It's beneficial to stay informed.
Yahoo
19-05-2025
- Business
- Yahoo
Huma sets stage for M&A strategy with Eckuity Capital partnership
British healthtech company Huma Therapeutics has partnered with Eckuity Capital to lay the foundations for an "aggressive" new M&A strategy. Huma develops AI-based tools for healthcare data integrations, patient wearables and other mobile devices to securely transmit data for use by healthcare professionals (HCPs). The company stated that its partnership with growth equity company Eckuity would support its development of technology infrastructure to support ongoing plans to acquire companies and launch digital solutions across the healthcare space. Huma also stated that its strategy will involve the ongoing acquisition of "complementary" companies to build a 'comprehensive digital ecosystem' that will support global health systems, CROs, and patients. According to Eckuity Capital managing partner Youssef Sebban, its role will be in helping Huma to acquire companies that 'may not fully realise' their potential on their own, yet become 'highly complementary' when integrated into Huma's cloud platform. Along with the Eckuity partnership, Huma has acquired Aluna (formerly Knox Medical Diagnostics). According to Huma, integrating the US company's respiratory monitoring offerings onto its platform will add 200 health systems and clinic chains to its existing 4,500 hospital network. Financial terms of the deal have not been publicly disclosed. Huma founder and CEO Dan Vahdat stated that its dual announcement marked a 'new chapter' for the company as it aims to build the world's 'most impactful' healthcare company. Vahdat said: 'By integrating Aluna's leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and most importantly, patients around the world." Aluna CEO Charvi Shetti said: 'Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide.' Huma received Class II clearance from the US Food and Drug Administration (FDA) for its platform as a software as a medical device (SaMD) in 2023, making it one of the first successful applicants to the FDA's eSTAR programme, in partnership with Health Canada. "Huma sets stage for M&A strategy with Eckuity Capital partnership" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Huma Announces Partnership with Eckuity Capital to Accelerate M&A and Acquires Aluna
New York, May 16, 2025 (GLOBE NEWSWIRE) -- Huma Therapeutics ('Huma'), the global healthcare AI leader accelerating digital transformation across care and research, today announced two major milestones: A global partnership agreement with Eckuity Capital to develop next-generation technology infrastructure—built on strong regulatory foundations—for the acquisition and launch of digital solutions in healthcare and research; and The acquisition of Aluna (also known as Knox Medical Diagnostics, Inc.), a leading U.S.-based company specializing in intelligent remote monitoring and management of respiratory x Aluna: (Front row, L to R) Charvi Shetty CEO of Aluna with Dan Vahdat CEO of Huma. Accelerating Growth Through M&ATo fuel its continued expansion, Huma is announcing partnership and investment with Eckuity Capital. This strategic collaboration with a leading healthcare growth equity firm will help provide the resources necessary to advance Huma's aggressive M&A strategy, with the goal of acquiring complementary companies to build a comprehensive digital ecosystem supporting health systems, pharmaceutical companies, CROs, and patients worldwide. Youssef Sebban, Managing Partner at Eckuity Capital, said: 'We help Huma acquire companies that, on their own, may not fully realize their potential—but when integrated into Huma's cloud platform, become highly complementary and transformative. This synergy not only amplifies their impact on the healthcare ecosystem but also drives outsized value creation for investors and shareholders.' Dan Vahdat, Founder and CEO of Huma, said: 'Today's announcements mark a new chapter for Huma as we strive to build the most impactful healthcare company in the world. By integrating Aluna's leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and—most importantly—patients around the world.' Huma's award-winning, disease-agnostic cloud platform has earned major regulatory certifications, including FDA 510(k) Class II and EU MDR Class IIb status. It supports over 4,500 hospitals and clinics and engages more than 50 million individuals across 70+ countries. Huma plays a pivotal role in national healthcare initiatives across the U.S., U.K., Germany, Greece, and Saudi Arabia, partnering with leading health systems, pharmaceutical companies, and CROs to redefine healthcare delivery. Strengthening Respiratory Health CapabilitiesWith the acquisition of Aluna, Huma significantly expands its reach in respiratory health, adding over 150 U.S.-based health systems and clinic networks to its growing global footprint. Based in San Francisco, Aluna is a market leader in respiratory patient monitoring and medical device manufacturing, including its proprietary spirometers. As part of the integration, Aluna's solutions will be relaunched on the Huma Cloud Platform, further enhancing their capabilities. The Huma Cloud Platform enables seamless, code-free configuration and AI/ML integration across a wide range of disease areas. The upgrade will also elevate Aluna's product classification to FDA Class II, unlocking greater clinical value for both patients and providers. All existing Aluna customers will gain access to Huma's comprehensive portfolio of disease management programs—spanning asthma, COPD, sleep apnea, and related conditions—serving approximately 500,000 contracted lives across these areas. This strategic move positions Huma to better serve the more than 25 million asthma patients and 15 million COPD patients in the United States alone, while reinforcing its leadership in chronic respiratory care on a global scale. Charvi Shetty, CEO of Aluna, remarked: 'Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide. We are excited about the prospect of integrating our technology into the Huma Cloud Platform, creating a truly holistic digital health solution that empowers both patients and healthcare professionals in the effective management of respiratory conditions.' Vishal Jain, Managing Partner at Eckuity Capital, said: 'We believe Dan and Huma's leadership team brings the much-needed bold vision to develop one of the most meaningful healthcare companies of the 21st century. The AI-led transformation of care that we will witness over the next two decades needs a reliable, real-time, and responsive infrastructure that very few companies can offer globally, and Huma is one of the most capable companies that can deliver on this promise.' Goodwin Proctor was exclusive legal advisor to Huma Therapeutics Limited on the Aluna transaction. Peak Technology Partners served as the exclusive financial advisor to Aluna on the transaction. Ends Media images are here. About HumaHuma is a healthcare AI company that owns and operates leading digital health applications. Its portfolio powers health systems, pharmaceutical companies, and CROs across more than 70 countries, transforming healthcare delivery at scale. Huma's disease-agnostic cloud platform is designed for rapid, no-code configuration and AI/ML integration, and has been recognized with FDA 510(k) Class II, EU/MDR Class IIb, and other major regulatory certifications. These capabilities enable the company to quickly launch new use cases and optimize acquired assets. Learn more at About Eckuity CapitalEckuity Capital is a global healthcare investment firm that supports high-growth companies at the inflection point in their growth cycle. The firm invests across Medtech, HealthTech, and Biotech Services to make a meaningful difference to patients, providers, and payors. With offices in New York and London, the firm focuses on solutions that bring positive changes to productivity, efficacy, distribution, and efficiency across the healthcare ecosystem. About AlunaAluna provides an AI-powered remote patient monitoring solution, integrating a portable, FDA-cleared spirometer, an intuitive mobile application, and a clinician portal. This integrated system enables live, real-world tracking of lung function and respiratory health. Developed by UC Berkeley Engineering graduates with firsthand experience of respiratory conditions, Aluna prioritizes user-friendliness and engagement, incorporating interactive features and rewards to encourage consistent use and adherence. Aluna's provider dashboard allows doctors to remotely access patient data, enhancing telemedicine capabilities and offering valuable health insights. The collection of real-time data in everyday settings allows for the assessment of respiratory medication and therapy effectiveness for individuals affected by asthma, COPD, cystic fibrosis, and other respiratory conditions. CONTACT: For further information please contact the Huma press office: Bilal Mahmood on or +44 (0) 771 400 7257.
Indian Express
16-05-2025
- Entertainment
- Indian Express
Huma Qureshi opens up about pay disparity on OTT: ‘Maharani is possibly the most-watched show, but do I get paid as much as my male counterparts?'
Huma Qureshi has firmly cemented her place in the digital entertainment space with her standout performance in the critically acclaimed OTT series Maharani. Her portrayal of Rani Bharti resonated deeply with audiences, helping the show gain massive popularity. In a recent conversation with India Today, she opened up about how the OTT boom has transformed careers for actors like her — and also spotlighted a critical issue plaguing the industry: pay disparity. 'Maharani is possibly the most watched show and the most loved show,' Huma said. 'But do I get paid as much as my male counterparts who are doing an OTT show? Far from it. So that's still a space one needs to negotiate. And it's very unfortunate. But it is a reality.' She didn't shy away from pointing out the stark pay gap between male and female leads, even in cases where the female actor carries the show. 'I am the number one on the show. But I'm saying, if I'm comparing another show with any male-led show, they would be paid far more. I keep hearing about male actors getting ₹45 crores, and I'm like, why?' Shared post on Time Also Read | Huma Qureshi feels some actors are 'only talking about process and not acting': 'I'm not trying to be catty but…' When asked why such disparities persist, Huma said, 'There is no reason given. It's just how things are.' However, she remains optimistic that things can change if the conversation continues. 'I think all of us collectively are talking about it. And all of us, I think, are rejecting substandard content. And I'm talking more about relevant stories that need to be told.' While she acknowledged the opportunities that OTT platforms have created for talents like Jaideep Ahlawat, Shefali Shah, and herself, she also expressed concern that the space is becoming too generic. She stressed the need for reinvention in storytelling to keep the medium fresh and meaningful.
